Hyaluronic acid-based drug conjugates: State-of-the-art and perspectives

Journal of Biomedical Nanotechnology

Volumn 10, Issue 1, 2014, Pages 4-16

  Chen, Bo ^a   Miller, Robert J ^a   Dhal, Pradeep K ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Cancer; Cell surface receptor; Drug conjugate; Glycosaminoglycan; Hyaluronic Acid (HA); Inflammation; Local delivery; Osteoarthritis; Targeted delivery

Indexed keywords

CANCER; CELL SURFACE RECEPTORS; DRUG-CONJUGATES; GLYCOSAMINOGLYCANS; INFLAMMATION; LOCAL DELIVERY; OSTEOARTHRITIS; TARGETED DELIVERY;

BIOCOMPATIBILITY; CELL MEMBRANES; FUNCTIONAL GROUPS; FUNCTIONAL POLYMERS; MOLECULES; ORGANIC ACIDS;

HYALURONIC ACID;

'TAXOL'; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUPIVACAINE; DOXORUBICIN; EXENDIN 4; HERMES ANTIGEN; HYALURONIC ACID; LIPOSOME; MACROGOL; MESSENGER RNA; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY; MORPHINE; NALOXONE; PACLITAXEL; POLYGLUTAMIC ACID; RECOMBINANT GROWTH HORMONE; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANALGESIA; ARTHRITIS; CONFOCAL MICROSCOPY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; FOOD INTAKE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; REVIEW;

ANALGESICS, OPIOID; ANIMALS; ARTHRALGIA; CROSS-LINKING REAGENTS; DRUG ADMINISTRATION ROUTES; GENE TRANSFER TECHNIQUES; HUMANS; HYALURONIC ACID; NANOCONJUGATES; POLYMERS;

EID: 84889063240     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1781     Document Type: Review

References (102)

1. R. Tammi, U. M. Agren, A. L. Tuhkanen, and M. Tammi, Hyaluronan metabolism in skin. Prog. Histochem. Cytochem. 29, 1 (1994).
2. M. B. Brown and S. A. Jones, Hyaluronic acid: A unique topical vehicle for the localized delivery of drugs to the skin. J. Eur. Acad. Dermatol. Venereol. 19, 308 (2005).
3. J. Y. Lee and A. P. Spicer, Hyaluronan: A multifunctional, megadalton, stealth molecule. Curr. Opin. Cell Biol. 12, 581 (2000).
4. N. Yamada, M. Uzuki, A. Rikimaru, M. Sakurai, and T. Sawai, Increased levels of circulating hyaluronate in the sera of patients with rheumatoid arthritis with special reference to joint destruction. Ryumachi 34, 752 (1994).
5. D. A. Ossipov, Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert. Opin. Drug. Deliv. 7, 681 (2010).
6. R. Stern, Devising a pathway for hyaluronan catabolism: Are we there yet?. Glycobiology 13, 105R (2003).
7. W. Knudson, G. Chow, and C. B. Knudson, Cd44-mediated uptake and degradation of hyaluronan. Matrix. Biol. 21, 15 (2002).
8. D. Ruhela, K. Riviere, and F. C. Szoka, Jr., Efficient synthesis of an aldehyde functionalized hyaluronic acid and its application in the preparation of hyaluronan-lipid conjugates. Bioconjug. Chem. 17, 1360 (2006).
9. S. Misra, P. Heldin, V. C. Hascall, N. K. Karamanos, S. S. Skandalis, R. R. Markwald, and S. Ghatak, Hyaluronan-cd44 interactions as potential targets for cancer therapy. FEBS J. 278, 1429 (2011).
10. B. P. Toole, Hyaluronan-cd44 interactions in cancer: Paradoxes and possibilities. Clin. Cancer Res. 15, 7462 (2009).
11. V. Abetamann, H. F. Kern, and H. P. Elsasser, Differential expression of the hyaluronan receptors cd44 and rhamm in human pancreatic cancer cells. Clin. Cancer Res. 2, 1607 (1996).
12. V. M. Platt and F. C. Szoka, Jr., Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or cd44, a hyaluronan receptor. Mol. Pharm. 5, 474 (2008).
13. G. D. Prestwich, Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J. Control Release 155, 193 (2011).
14. G. Journo-Gershfeld, D. Kapp, Y. Shamay, J. Kopecek, and A. David, Hyaluronan oligomers-hpma copolymer conjugates for targeting paclitaxel to cd44-overexpressing ovarian carcinoma. Pharm. Res. 29, 1121 (2012).
15. A. Banzato, M. Rondina, L. Melendez-Alafort, E. Zangoni, A. Nadali, D. Renier, G. Moschini, U. Mazzi, P. Zanovello, and A. Rosato, Biodistribution imaging of a paclitaxel-hyaluronan bio-conjugate. Nucl. Med. Biol. 36, 525 (2009).
16. A. M. Al-Ghananeem, A. H. Malkawi, Y. M. Muammer, J. M. Balko, E. P. Black, W. Mourad, and E. Romond, Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech. 10, 410 (2009).
17. A. Banzato, S. Bobisse, M. Rondina, D. Renier, F. Bettella, G. Esposito, L. Quintieri, L. Melendez-Alafort, U. Mazzi, P. Zanovello, and A. Rosato, A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 14, 3598 (2008).
18. A. Serafino, M. Zonfrillo, F. Andreola, R. Psaila, L. Mercuri, N. Moroni, D. Renier, M. Campisi, C. Secchieri, and P. Pierimarchi, Cd44-targeting for antitumor drug delivery: A new sn-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. Curr. Cancer Drug Targets 11, 572 (2011).
19. J. M. Terwogt, O. van Tellingen, V. R. Nannan Panday, M. T. Huizing, J. H. Schellens, W. W. ten Bokkel Huinink, M. U. Boschma, G. Giaccone, C. H. Veenhof, and J. H. Beijnen, Cremophor el pharmacokinetics in a phase i study of paclitaxel (taxol) and carboplatin in non-small cell lung cancer patients. Anticancer Drugs 11, 687 (2000).
20. J. Liebmann, J. A. Cook, C. Lipschultz, D. Teague, J. Fisher, and J. B. Mitchell, The influence of cremophor el on the cell cycle effects of paclitaxel (taxol) in human tumor cell lines. Cancer Chemother. Pharmacol. 33, 331 (1994).
21. C. E. Galer, D. Sano, S. C. Ghosh, J. H. Hah, E. Auzenne, A. N. Hamir, J. N. Myers, and J. Klostergaard, Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol. 47, 1039 (2011).
22. G. Esposito, S. G. Crich, and S. Aime, Efficient cellular labeling by cd44 receptor-mediated uptake of cationic liposomes functionalized with hyaluronic acid and loaded with mri contrast agents. ChemMedChem. 3, 1858 (2008).
23. Y. Kim, Y. S. Lee, J. H. Hahn, J. Choe, H. J. Kwon, J. Y. Ro, and D. Jeoung, Hyaluronic acid targets cd44 and inhibits fcepsilonri signaling involving pkcdelta, rac1, ros, and mapk to exert anti-allergic effect. Mol. Immunol. 45, 2537 (2008).
24. R. Golshani, L. Lopez, V. Estrella, M. Kramer, N. Iida, and V. B. Lokeshwar, Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through cd44. Cancer Res. 68, 483 (2008).
25. H. Harada and M. Takahashi, Cd44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J. Biol. Chem. 282, 5597 (2007).
26. K. Higa, S. Shimmura, J. Shimazaki, and K. Tsubota, Hyaluronic acid-cd44 interaction mediates the adhesion of lymphocytes by amniotic membrane stroma. Cornea 24, 206 (2005).
27. T. Ahrens, V. Assmann, C. Fieber, C. Termeer, P. Herrlich, M. Hofmann, and J. C. Simon, Cd44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J. Invest. Dermatol. 116, 93 (2001).
28. D. Park, Y. Kim, H. Kim, K. Kim, Y. S. Lee, J. Choe, J. H. Hahn, H. Lee, J. Jeon, C. Choi, Y. M. Kim, and D. Jeoung, Hyaluronic acid promotes angiogenesis by inducing rhamm-tgfbeta receptor interaction via cd44-pkcdelta. Mol. Cells 33, 563 (2012).
29. K. Kouvidi, A. Berdiaki, D. Nikitovic, P. Katonis, N. Afratis, V. C. Hascall, N. K. Karamanos, and G. N. Tzanakakis, Role of receptor for hyaluronic acid-mediated motility (rhamm) in low molecular weight hyaluronan (lmwha)-mediated fibrosarcoma cell adhesion. J. Biol. Chem. 286, 38509 (2011).
30. J. Greiner, L. Li, M. Ringhoffer, T. F. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt, Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (rhamm/cd168) recognized by cd8+ t cells of hla-a2-positive patients with acute myeloid leukemia. Blood 106, 938 (2005).
31. D. J. Bagli, B. D. Joyner, S. R. Mahoney, and L. McCulloch, The hyaluronic acid receptor rhamm is induced by stretch injury of rat bladder in vivo and influences smooth muscle cell contraction in vitro [corrected]. J. Urol. 162, 832 (1999).
32. H. B. Nair, S. Huffman, P. Veerapaneni, N. B. Kirma, P. Binkley, R. P. Perla, D. B. Evans, and R. R. Tekmal, Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice. J. Nanosci. Nanotechnol. 11, 3789 (2011).
33. E. Auzenne, S. C. Ghosh, M. Khodadadian, B. Rivera, D. Farquhar, R. E. Price, M. Ravoori, V. Kundra, R. S. Freedman, and J. Klostergaard, Hyaluronic acid-paclitaxel: Antitumor efficacy against cd44(+) human ovarian carcinoma xenografts. Neoplasia 9, 479 (2007).
34. H. Maeda, Macromolecular therapeutics in cancer treatment: The epr effect and beyond. J. Control Release 16, 4138 (2012).
35. K. Greish, Enhanced permeability and retention (epr) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol. 624, 25 (2010).
36. E. N. Harris, B. A. Baggenstoss, and P. H. Weigel, Rat and human hare/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins. Am. J. Physiol. Gastrointest Liver Physiol. 296, G1191 (2009).
37. E. N. Harris, J. A. Weigel, and P. H. Weigel, The human hyaluronan receptor for endocytosis (hare/stabilin-2) is a systemic clearance receptor for heparin. J. Biol. Chem. 283, 17341 (2008).
38. B. Zhou, J. A. Weigel, L. Fauss, and P. H. Weigel, Identification of the hyaluronan receptor for endocytosis (hare). J. Biol. Chem. 275, 37733 (2000).
39. E. Svanovsky, V. Velebny, A. Laznickova, and M. Laznicek, The effect of molecular weight on the biodistribution of hyaluronic acid radiolabeled with 111in after intravenous administration to rats. Eur. J. Drug Metab. Pharmacokinet. 33, 149 (2008).
40. M. N. Courel, N. Girard, J. Chomant, J. C. Liehn, and B. Delpech, 111in-hyaluronectin, a new probe for radiodetection of tumours: Biodistribution and imaging in grafted mice. J. Nucl. Biol. Med. 37, 88 (1993).
41. F. Piccioni, M. Malvicini, M. G. Garcia, A. Rodriguez, C. Atorrasagasti, N. Kippes, I. T. Piedra Buena, M. M. Rizzo, J. Bayo, J. Aquino, M. Viola, A. Passi, L. Alaniz, and G. Mazzolini, Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology 22, 400 (2012).
42. K. S. Kim, W. Hur, S. J. Park, S. W. Hong, J. E. Choi, E. J. Goh, S. K. Yoon, and S. K. Hahn, Bioimaging for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano 4, 3005 (2010).
43. I. De Stefano, A. Battaglia, G. F. Zannoni, M. G. Prisco, A. Fattorossi, D. Travaglia, S. Baroni, D. Renier, G. Scambia, C. Ferlini, and D. Gallo, Hyaluronic acid-paclitaxel: Effects of intraperitoneal administration against cd44(+) human ovarian cancer xenografts. Cancer Chemother. Pharmacol. 68, 107 (2011).
44. J. Yamada, J. Kitayama, N. H. Tsuno, H. Yamashita, H. Miyato, D. Soma, K. Otani, T. Kamei, H. Ishigami, A. Hidemura, S. Kaisaki, K. Takahashi, and H. Nagawa, Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle - a new strategy against peritoneal dissemination of gastric cancer. Cancer Lett. 272, 307 (2008).
45. G. Tringali, F. Bettella, M. C. Greco, M. Campisi, D. Renier, and P. Navarra, Pharmacokinetic profile of oncofid-s after intraperitoneal and intravenous administration in the rat. J. Pharm. Pharmacol. 64, 360 (2012).
46. D. Peer and R. Margalit, Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6, 343 (2004).
47. D. Peer and R. Margalit, Loading mitomycin c inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 108, 780 (2004).
48. R. E. Eliaz, S. Nir, and F. C. Szoka, Jr., Interactions of hyaluronan-targeted liposomes with cultured cells: Modeling of binding and endocytosis. Methods Enzymol. 387, 16 (2004).
49. R. E. Eliaz and F. C. Szoka, Jr., Liposome-encapsulated doxorubicin targeted to cd44: A strategy to kill cd44-overexpressing tumor cells. Cancer Res. 61, 2592 (2001).
50. H. S. Qhattal and X. Liu, Characterization of cd44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol. Pharm. 8, 1233 (2011).
51. A. K. Yadav, P. Mishra, A. K. Mishra, S. Jain, and G. P. Agrawal, Development and characterization of hyaluronic acid-anchored plga nanoparticulate carriers of doxorubicin. Nanomedicine 3, 246 (2007).
52. R. J. Fontana, J. L. Dienstag, H. L. Bonkovsky, R. K. Sterling, D. Naishadham, Z. D. Goodman, A. S. Lok, E. C. Wright, and G. L. Su, Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis c. Gut 59, 1401 (2010).
53. L. Zhang, J. Yao, J. Zhou, T. Wang, and Q. Zhang, Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Int. J. Pharm. 441, 654 (2012).
54. K. Y. Choi, K. H. Min, H. Y. Yoon, K. Kim, J. H. Park, I. C. Kwon, K. Choi, and S. Y. Jeong, Pegylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 32, 1880 (2011).
55. J. A. Yang, K. Park, H. Jung, H. Kim, S. W. Hong, S. K. Yoon, and S. K. Hahn, Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis c virus infection. Biomaterials 32, 8722 (2011).
56. R. M. Bukowski, C. Tendler, D. Cutler, E. Rose, M. M. Laughlin, and P. Statkevich, Treating cancer with peg intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 95, 389 (2002).
57. J. R. Fraser, T. C. Laurent, and U. B. Laurent, Hyaluronan: Its nature, distribution, functions and turnover. J. Intern. Med. 242, 27 (1997).
58. J. Necas, L. Bartosikova, P. Brauner, and J. Kolar, Hyaluronic acid (hyaluronan): A review. Veterinarni Medicina 53, 397 (2008).
59. P. K. Dhal, D. A. Gianolio, and R. J. Miller, (Bio) polymeric hydrogels as therapeutic agents. J. Macromol. Sci., Part A 48, 994 (2011).
60. P. K. Dhal, D. A. Gianolio and R. J. Miller, Polymer based therapies for the treatment of chronic pain, in Pain Management - Current Issues and Opinions, edited by B. R. Gabor and E. N. Carl, InTech, Rijeka, Croatia, DOI: 10.5772/29882 (2012), Chapter 2.
61. L. J. Crofford, Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nat. Rev. Rheumatol. 6, 191 (2010).
62. Z. Merza, Chronic use of opioids and the endocrine system. Hormone and Metabolic Research 42, 621 (2010).
63. A. Homma, H. Sato, T. Tamura, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T. Matsuura, S. Sato, Y. Higuchi, T. Watanabe, H. Kitamura, K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H. Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, and R. Suzuki, Synthesis and optimization of hyaluronic acid-methotrexate conjugates to maximize benefit in the treatment of osteoarthritis. Bioorg. Med. Chem. 18, 1062 (2010).
64. A. Homma, H. Sato, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T. Matsuura, S. Sato, T. Tamura, Y. Higuchi, T. Watanabe, H. Kitamura, K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H. Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, and R. Suzuki, Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment. Bioorg. Med. Chem. 17, 4647 (2009).
65. J. Swierkot and J. Szechinski, Methotrexate in rheumatoid arthritis. Pharmacol. Rep. 58, 473 (2006).
66. D. A. Gianolio, M. Philbrook, L. Z. Avila, L. E. Young, L. Plate, M. R. Santos, R. Bernasconi, H. Liu, S. Ahn, W. Sun, P. K. Jarrett, and R. J. Miller, Hyaluronan-tethered opioid depots: Synthetic strategies and release kinetics in vitro and in vivo. Bioconjug. Chem. 19, 1767 (2008).
67. D. A. Gianolio, M. Philbrook, L. Z. Avila, H. MacGregor, S. X. Duan, R. Bernasconi, M. Slavsky, S. Dethlefsen, P. K. Jarrett, and R. J. Miller, Synthesis and evaluation of hydrolyzable hyaluronan-tethered bupivacaine delivery systems. Bioconjug. Chem. 16, 1512 (2005).
68. L. T. Sun, K. S. Buchholz, M. T. Lotze, and N. R. Washburn, Cytokine binding by polysaccharide-antibody conjugates. Mol. Pharm. 7, 1769 (2010).
69. L. T. Sun, S. A. Bencherif, T. W. Gilbert, M. T. Lotze, and N. R. Washburn, Design principles for cytokine-neutralizing gels: Cross-linking effects. Acta Biomater. 6, 4708 (2010).
70. L. T. Sun, S. A. Bencherif, T. W. Gilbert, A. M. Farkas, M. T. Lotze, and N. R. Washburn, Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates. Wound Repair Regen. 18, 302 (2010).
71. P. Karande and S. Mitragotri, Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim. Biophys. Acta. 1788, 2362 (2009).
72. T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori, Anti-tnf antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275 (2006).
73. L. Han, Y. Zhao, L. Yin, R. Li, Y. Liang, H. Huang, S. Pan, C. Wu, and M. Feng, Insulin-loaded ph-sensitive hyaluronic acid nanoparticles enhance transcellular delivery. AAPS PharmSciTech. 13, 836 (2012).
74. S. Rajapaksa, D. McIntosh, A. Cowin, D. Adams, and P. J. Wormald, The effect of insulin-like growth factor 1 incorporated into a hyaluronic acid-based nasal pack on nasal mucosal healing in a healthy sheep model and a sheep model of chronic sinusitis. Am. J. Rhinol. 19, 251 (2005).
75. T. Nakai, T. Hirakura, Y. Sakurai, T. Shimoboji, M. Ishigai, and K. Akiyoshi, Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel. Macromol. Biosci. 12, 475 (2012).
76. J. H. Kong, E. J. Oh, S. Y. Chae, K. C. Lee, and S. K. Hahn, Long acting hyaluronate - exendin 4 conjugate for the treatment of type 2 diabetes. Biomaterials 31, 4121 (2010).
77. R. S. Cvetkovic and G. L. Plosker, Exenatide: A review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 67, 935 (2007).
78. A. Bond, Exenatide (byetta) as a novel treatment option for type 2 diabetes mellitus. Proc. (Bayl. Univ. Med. Cent.) 19, 281 (2006).
79. P. H. Kim and S. W. Kim, Polymer-based delivery of glucagon-like peptide-1 for the treatment of diabetes. ISRN Endocrinol. 2012, 340632 (2012).
80. B. Elsadek and F. Kratz, Impact of albumin on drug delivery-new applications on the horizon. J. Control Release 157, 4 (2012).
81. M. Fineman, S. Flanagan, K. Taylor, M. Aisporna, L. Z. Shen, K. F. Mace, B. Walsh, M. Diamant, B. Cirincione, P. Kothare, W. I. Li, and L. MacConell, Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin. Pharmacokinet. 50, 65 (2011).
82. D. Kim, L. MacConell, D. Zhuang, P. A. Kothare, M. Trautmann, M. Fineman, and K. Taylor, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30, 1487 (2007).
83. T. H. Kim, H. H. Jiang, S. M. Lim, Y. S. Youn, K. Y. Choi, S. Lee, X. Chen, Y. Byun, and K. C. Lee, Site-specific pegylated exendin-4 modified with a high molecular weight trimeric peg reduces steric hindrance and increases type 2 antidiabetic therapeutic effects. Bioconjug. Chem. 23, 2214 (2012).
84. T. H. Kim, C. W. Park, H. Y. Kim, M. H. Chi, S. K. Lee, Y. M. Song, H. H. Jiang, S. M. Lim, Y. S. Youn, and K. C. Lee, Low molecular weight (1 kda) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice. Biol. Pharm. Bull. 35, 1076 (2012).
85. T. H. Claus, C. Q. Pan, J. M. Buxton, L. Yang, J. C. Reynolds, N. Barucci, M. Burns, A. A. Ortiz, S. Roczniak, J. N. Livingston, K. B. Clairmont, and J. P. Whelan, Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. J. Endocrinol. 192, 371 (2007).
86. F. M. Veronese and G. Pasut, Pegylation, successful approach to drug delivery. Drug Discov. Today 10, 1451 (2005).
87. K. Akiyoshi, S. Deguchi, H. Tajima, T. Nishikawa, and J. Sunamoto, Microscopic structure and thermoresponsiveness of a hydrogel nanoparticle by self-assembly of a hydrophobized polysaccharide. Macromolecules 30, 857 (1997).
88. K. Akiyoshi, Y. Sasaki, and J. Sunamoto, Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: Thermal stabilization with refolding of carbonic anhydrase b. Bioconjug. Chem. 10, 321 (1999).
89. X. G. Gu, M. Schmitt, A. Hiasa, Y. Nagata, H. Ikeda, Y. Sasaki, K. Akiyoshi, J. Sunamoto, H. Nakamura, and K. Kuribayashi, A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against her2-expressing murine sarcomas. Cancer Res. 58, 3385 (1998).
90. T. Shimizu, T. Kishida, U. Hasegawa, Y. Ueda, J. Imanishi, H. Yamagishi, K. Akiyoshi, E. Otsuji, and O. Mazda, Nanogel dds enables sustained release of il-12 for tumor immunotherapy. Biochem. Biophys. Res. Commun. 367, 330 (2008).
91. K. Gavrilov and W. M. Saltzman, Therapeutic sirna: Principles, challenges, and strategies. Yale J. Biol. Med. 85, 187 (2012).
92. M. Ameyar-Zazoua, V. Guasconi, and S. Ait-Si-Ali, Sirna as a route to new cancer therapies. Expert Opin. Biol. Ther. 5, 221 (2005).
93. H. M. Ali, G. Urbinati, M. Raouane, and L. Massaad-Massade, Significance and applications of nanoparticles in sirna delivery for cancer therapy. Expert Rev. Clin. Pharmacol. 5, 403 (2012).
94. A. Kumari, V. Kumar, and S. K. Yadav, Nanocarriers: A tool to overcome biological barriers in sirna delivery. Expert Opin. Biol. Ther. 11, 1327 (2011).
95. H. Mok, J. W. Park, and T. G. Park, Antisense oligodeoxynucleotide- conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. Bioconjug. Chem. 18, 1483 (2007).
96. M. Han, Q. Lv, X. J. Tang, Y. L. Hu, D. H. Xu, F. Z. Li, W. Q. Liang, and J. Q. Gao, Overcoming drug resistance of mcf-7/adr cells by altering intracellular distribution of doxorubicin via mvp knockdown with a novel sirna polyamidoamine-hyaluronic acid complex. J. Control Release 163, 136 (2012).
97. C. J. Chen, Z. X. Zhao, J. C. Wang, E. Y. Zhao, L. Y. Gao, S. F. Zhou, X. Y. Liu, W. L. Lu, and Q. Zhang, A comparative study of three ternary complexes prepared in different mixing orders of sirna/redox-responsive hyperbranched poly (amido amine)/hyaluronic acid. Int. J. Nanomedicine 7, 3837 (2012).
98. Y. Shen, B. Wang, Y. Lu, A. Ouahab, Q. Li, and J. Tu, A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (hhscs) for efficient receptor-mediated sirna delivery. Int. J. Pharm. 414, 233 (2011).
99. K. Park, M. Y. Lee, K. S. Kim, and S. K. Hahn, Target specific tumor treatment by vegf sirna complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials 31, 5258 (2010).
100. S. E. Han, H. Kang, G. Y. Shim, S. J. Kim, H. G. Choi, J. Kim, S. K. Hahn, and Y. K. Oh, Cationic derivatives of biocompatible hyaluronic acids for delivery of sirna and antisense oligonucleotides. J. Drug Target 17, 123 (2009).
101. G. Jiang, K. Park, J. Kim, K. S. Kim, E. J. Oh, H. Kang, S. E. Han, Y. K. Oh, T. G. Park, and S. K. Hahn, Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of sirna. Biopolymers 89, 635 (2008).
102. A. Pathak, A. Swami, S. Patnaik, S. Jain, K. Chuttani, A. K. Mishra, S. P. Vyas, P. Kumar, and K. C. Gupta, Efficient tumor targeting by polysaccharide decked polyethylenimine based nanocomposites. J. Biomed. Nanotechnol. 5, 264 (2009).